Prognostic relevance of MYD88 mutations in CLL: the jury is
still out

J 2015

Prognostic relevance of MYD88 mutations in CLL: the jury is still out

BALIAKAS, Panagiotis; Anastasia HADZIDIMITRIOU; Andreas AGATHANGELIDIS; Davide ROSSI; Lesley-Ann SUTTON et al.

Základní údaje

Originální název

Prognostic relevance of MYD88 mutations in CLL: the jury is still out

Autoři

Vydání

Blood, Washington DC, USA, American Society of Hematology, 2015, 0006-4971

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 11.847

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14740/15:00084815

Organizační jednotka

Středoevropský technologický institut

Klíčová slova anglicky

CHRONIC LYMPHOCYTIC-LEUKEMIA; GENES; SF3B1

Štítky

podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 1. 4. 2016 16:16, Mgr. Eva Špillingová

Anotace

V originále

Genome surveys have offered a comprehensive view of the genetic landscape of chronic lymphocytic leukemia (CLL), identifying several recurrently mutated genes, including myeloid differentiation primary response 88 (MYD88). The predominant mutation concerns a p.L265P substitution within exon 5,1,2 which leads to constitutive nuclear factor kappaB stimulation, thus conferring a proliferation and survival advantage to the mutant cells.1 MYD88 mutations reach up to 2% to 5% in CLL and are strikingly enriched among patients expressing mutated IGHV genes (M-CLL).

Návaznosti

ED1.1.00/02.0068, projekt VaV

Název: CEITEC - central european institute of technology

NT13493, projekt VaV

Název: Molekulární charakterizace B buněčných receptorů a jejich vztah k evoluci genetických změn u chronické lymfocytární leukémie

Přiložené soubory

ZVV_2015_115_1318319_Prognostic_relevance.pdf

Požádat o autorskou verzi souboru

Citovat

BALIAKAS, Panagiotis; Anastasia HADZIDIMITRIOU; Andreas AGATHANGELIDIS; Davide ROSSI; Lesley-Ann SUTTON; Jana KMÍNKOVÁ; Lydia SCARFO; Šárka POSPÍŠILOVÁ; Gianluca GAIDANO; Kostas STAMATOPOULOS; Paolo GHIA a Richard ROSENQUIST. Prognostic relevance of MYD88 mutations in CLL: the jury is still out. Blood. Washington DC, USA: American Society of Hematology, 2015, roč. 126, č. 8, s. 1043-1044. ISSN 0006-4971. Dostupné z: https://doi.org/10.1182/blood-2015-05-648634.

@article{1318319,
   author = {Baliakas, Panagiotis and Hadzidimitriou, Anastasia and Agathangelidis, Andreas and Rossi, Davide and Sutton, LesleyandAnn and Kmínková, Jana and Scarfo, Lydia and Pospíšilová, Šárka and Gaidano, Gianluca and Stamatopoulos, Kostas and Ghia, Paolo and Rosenquist, Richard},
   article_location = {Washington DC, USA},
   article_number = {8},
   doi = {https://doi.org/10.1182/blood-2015-05-648634},
   keywords = {CHRONIC LYMPHOCYTIC-LEUKEMIA; GENES; SF3B1},
   language = {eng},
   issn = {0006-4971},
   journal = {Blood},
   title = {Prognostic relevance of MYD88 mutations in CLL: the jury is still out},
   url = {http://www.bloodjournal.org/content/bloodjournal/126/8/1043.full.pdf},
   volume = {126},
   year = {2015}
}

TY  - JOUR
ID  - 1318319
AU  - Baliakas, Panagiotis - Hadzidimitriou, Anastasia - Agathangelidis, Andreas - Rossi, Davide - Sutton, Lesley-Ann - Kmínková, Jana - Scarfo, Lydia - Pospíšilová, Šárka - Gaidano, Gianluca - Stamatopoulos, Kostas - Ghia, Paolo - Rosenquist, Richard
PY  - 2015
TI  - Prognostic relevance of MYD88 mutations in CLL: the jury is still out
JF  - Blood
VL  - 126
IS  - 8
SP  - 1043-1044
EP  - 1043-1044
PB  - American Society of Hematology
SN  - 00064971
KW  - CHRONIC LYMPHOCYTIC-LEUKEMIA
KW  - GENES
KW  - SF3B1
UR  - http://www.bloodjournal.org/content/bloodjournal/126/8/1043.full.pdf
L2  - http://www.bloodjournal.org/content/bloodjournal/126/8/1043.full.pdf
N2  - Genome surveys have offered a comprehensive view of the genetic landscape of chronic lymphocytic leukemia (CLL), identifying several recurrently mutated genes, including myeloid differentiation primary response 88 (MYD88). The predominant mutation concerns a p.L265P substitution within exon 5,1,2 which leads to constitutive nuclear factor kappaB stimulation, thus conferring a proliferation and survival advantage to the mutant cells.1 MYD88 mutations reach up to 2% to 5% in CLL and are strikingly enriched among patients expressing mutated IGHV genes (M-CLL).
ER  -

BALIAKAS, Panagiotis; Anastasia HADZIDIMITRIOU; Andreas AGATHANGELIDIS; Davide ROSSI; Lesley-Ann SUTTON; Jana KMÍNKOVÁ; Lydia SCARFO; Šárka POSPÍŠILOVÁ; Gianluca GAIDANO; Kostas STAMATOPOULOS; Paolo GHIA a Richard ROSENQUIST. Prognostic relevance of MYD88 mutations in CLL: the jury is still out. \textit{Blood}. Washington DC, USA: American Society of Hematology, 2015, roč.~126, č.~8, s.~1043-1044. ISSN~0006-4971. Dostupné z: https://doi.org/10.1182/blood-2015-05-648634.

Přehled o publikaci